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Abstract 
According to class M2.1 of the World Anti-Doping Agency’s (WADA’s) Prohibited List, the 
manipulation of doping control urine samples to alter their integrity and validity is prohibited 
both in- and out-of-competition. However, some paraplegic athletes with an overactive bladder 
need to be regularly treated with anti-cholinergic and anti-spasmodic drugs such as oxybutynin, 
which are often administered intravesically to reduce the substantial side effects observed after 
oral application. So far, it remains unclear whether such bladder instillations have a negative 
impact on analytical procedures and thus represent an anti-doping rule violation.  
Within this pilot study, urine samples were collected from five paraplegic athletes before and 
after an intravesical oxybutynin hydrochloride instillation. The samples were routinely tested 
for the presence of performance-enhancing drugs and afterwards fortified with 25 model 
compounds representing different classes of doping agents (anabolic agents, cannabinoids, 
diuretics, glucocorticoids, hormone and metabolic modulators, and stimulants) at low and 
medium concentrations. Additionally, the pH-value and specific gravity were measured and 
the presence of oxybutynin was qualitatively determined by GC-MS.  
In initial testing procedures, all samples were tested negative. Oxybutynin was present in most 
of the samples but found to have no significant effect on the detectability of the 25 model 
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compounds subsequently added to each urine specimen. Therefore, it can be concluded that 
intravesical instillations with oxybutynin hydrochloride do not alter the integrity and validity 
of doping control urine samples. 
 
Short Title: Effects of intravesical instillations on the validity of doping control urine samples 
Keywords: Doping, Disability sports, Intravesical instillations, Manipulation, Oxybutynin  
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1. Introduction 
Many patients with spinal cord injuries additionally suffer from a neurogenic bladder with 
urinary incontinence [1]. The underlying overactivity and hyper-reflexia of the bladder detrusor 
muscle are routinely treated with clean intermittent catheterization and anti-cholinergic drugs 
such as oxybutynin [1-4]. This synthetic tertiary amine competitively binds to the M2 and M3 
muscarinic receptors on the detrusor smooth muscle cells, thus inhibiting cholinergic 
transmission. Moreover, oxybutynin has a direct muscle-relaxant effect mediated through 
calcium channel blockade and acts as local anesthetic [2, 4].  
Following systemic administration, the non-selective binding of oxybutynin and its main 
metabolite N-desethyl-oxybutynin to M1, M2, and M3 muscarinic receptors in other tissues 
such as the parotid gland, the cerebral cortex, and the heart often results in undesirable effects 
including, for example, dryness of the mouth, dizziness, drowsiness, and palpitations [2, 3]. By 
contrast, intravesical instillations with oxybutynin were found to provide a comparable clinical 
efficacy with minimized anti-cholinergic side-effects due to circumvention of the hepatic first 
pass metabolism [2, 3]. Especially for patients already using clean intermittent catheterization, 
it represents a convenient treatment alternative [2-4]. Usually, up to 30 mL of a saline solution 
containing several milligrams of oxybutynin are instilled through the urethra by using an 
intravesical catheter and retained in the bladder until the next catherization/voiding of urine 
(Figure 1).  
Also some paraplegic athletes have a neurogenic bladder and therefore perform regular 
intravesical oxybutynin instillations. However, according to the World Anti-Doping Agency’s 
(WADA’s) Prohibited List [5], urine tampering including substitution and adulteration is 
prohibited both in- and out-of-competition. As the composition of urine can be significantly 
altered by intravesical instillations, this therapeutic strategy can potentially be considered as a 
violation of anti-doping rules. Hence, the aim of this pilot study was to investigate whether 
bladder instillations - conducted shortly before a doping control or on a regular basis - have a 
negative effect on the integrity and analysis of the collected urine samples.  
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2. Material and methods 
2.1 Sample collection 
Six sets of urine samples were collected from five paraplegic athletes (three male athletes, two 
female athletes) before and after a therapeutic intravesical instillation with oxybutynin 
hydrochloride. For an intra-individual comparison, one subject delivered two sample sets (XD 
and XE, Table 1). As shown in Figure 2, the participants were asked to collect 50-80 mL of 
the last urine catheterized prior to the bladder instillation (P0) as well as up to three samples 
after the treatment (P1-P3) according to their individual catheterization schedule. The 
oxybutynin hydrochloride concentration of the solution ranged from 0.025% to 0.1% and 
volumes between 7.5 ml and 20.0 mL were instilled, depending on the athletes’ individual 
therapeutic regimen (Table 1). Following collection, urine samples were stored at 4°C and sent 
to the laboratory within 48 hours.  
 
2.2 Sample analysis & data evaluation 
All urine samples were tested for the presence of performance-enhancing drugs by using 
established analytical procedures [6-9] and the concentrations and ratios of natural/endogenous 
steroids (contributing to the so-called steroid profile) were determined by GC-MS(/MS) and 
specific gravity-adjusted [9, 10]. pH-Value and specific gravity were measured by using a 
DMA 38 Density Meter (Anton Paar, Graz, Austria), a Consort C3010 Analyzer (Thermo 
Fisher Scientific, Waltham, MA), and a PS61 autosampler (MLE, Dresden, Germany). The 
presence of oxybutynin was qualitatively determined by GC-MS.  
To investigate the direct effects of intravesical oxybutynin instillations on the detectability of 
doping agents, all samples (subjects XA-XF, samples P0-P3) were subsequently fortified with 
25 model compounds representing different classes of doping agents (anabolic agents, 
cannabinoids, diuretics, glucocorticoids, hormone and metabolic modulators, and stimulants) 
at low and medium concentrations (Table 2) and re-analyzed by means of routine doping 
control LC-MS and GC-MS methods.   
The acquired data was evaluated with regard to the following aspects: 
 Presence of prohibited substances 
  
This article is protected by copyright. All rights reserved. 
 Normal physiological steroid profiles 
 Normal specific gravity & pH values 
 Presence of oxybutynin 
 Detectability of the added model compounds; Intra-/Inter-individual differences (e.g. 
with regard to the signal intensities or the presence of interferences) 
 
3. Results and discussion 
All samples were routinely tested for the presence of commonly monitored performance-
enhancing drugs by using different GC-MS and LC-MS approaches. As shown in Table 2, all 
samples were tested negative in the initial testing procedures. The pH and specific gravity 
values ranged from pH 5.4-7.3 and 1.004-1.025, respectively (Table 1), and no significant 
differences were observed between the samples collected before and after the bladder 
instillation. This also applies to the steroid profile data, which are summarized in Supporting 
Information Table 1: Both before and following oxybutynin instillation, all markers 
(androsterone [A], etiocholanolone [ETIO], 5α-androstane-3α,17β-diol [Adiol], 5β-
androstane-3α,17β-diol [Bdiol], epitestosterone [E], and testosterone [T]) and ratios (T/E, 
Adiol/Bdiol, A/ETIO, A/T, & A/E) were below the applicable thresholds [11]. However, in 
one male subject (XC), the steroid profile of the sample collected prior to the oxybutynin 
treatment (P0) was characterized by an elevated level of testosterone (> 200 ng/mL) that would, 
in case of an authentic doping control scenario, lead to a “Suspicious Steroid Profile 
Confirmation Procedure Request” (SSP-CPR) including GC-MS or GC-MS/MS quantification 
and GC/C/IRMS analysis [11]. The remaining markers and ratios – except for A/T – were 
below the respective thresholds and all other subsequent samples were found unsuspicious. 
Oxybutynin was present in most of the urine specimens and as to be expected, the highest 
amounts were detected in the first samples (P1) collected 57-300 min after the intravesical 
instillation of the drug (Table 1). In three sample sets (XD, XE, & XF), also the samples 
obtained before the oxybutynin treatment contained significant amounts of the drug, arguably 
remainders of prior treatments. Oxybutynin could not be detected in two samples collected 
before the bladder instillation (XA-P0 and XC-P0) as well as one of the last samples collected 
after the treatment (XD-P3). Here, the absence of oxybutynin can probably be attributed to the 
collection time after the last instillation (XA-P0: > 25 h; XB-P0: > 15 h; XD-P3: > 8 h).  
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Following initial testing, 25 model compounds were added to the urine specimens at two 
different concentration levels. Sample re-analysis demonstrated that neither the presence of 
oxybutynin nor the intravesically retained fluid had any significant impact on the detectability 
of the different model compounds (Table 2). No systematic intra- or inter-individual 
differences were observed. In a few samples, the exogenous anabolic androgenic steroids 18-
nor-oxandrolone and epi-/trenbolone could not be detected, especially when spiked at low 
concentrations (2 and 1 ng/mL) below the WADA minimum required performance level 
(MRPL) of 5 ng/mL [12]. In case of Epi-/Trenbolone, this phenomenon could be observed in 
samples collected both before and following oxybutynin treatment. Consequently, it was 
attributed to occasionally observed matrix effects. By contrast, NorOxandrolone could not be 
detected in a total of two samples – XB-P1 fortified at low and medium concentration (2 and 
10 ng/mL) and XF-P1 fortified at low concentration (2 ng/mL). As NorOxandrolone was 
unambiguously detected in the other four samples (XA-P1, XC-P1, XD-P1, and XE-P1), it 
appears unlikely that the presence of oxybutynin was interfering with the detection of the drug. 
But as it cannot be ruled out with absolute certainty, further studies with more participants 
should be conducted in the future.  
In Figure 3, the extracted ion chromatograms of the diuretic hydrochlorothiazide for an 
exemplary sample set (XD) are displayed. As expected, both the samples collected before and 
after the intravesical oxybutynin hydrochloride instillation were tested negative for 
hydrochlorothiazide. When the analyte was added to the samples, low (20 ng/mL) and medium 
(100 ng/mL) level concentrations of the diuretic were unambiguously detected. Altogether, 
these findings indicate that neither intravesical instillations conducted on a regular basis and 
shortly before a doping control, nor the concomitant use of oxybutynin hydrochloride do alter 
the integrity and validity of doping control urine samples.  
 
4. Conclusions 
Many paraplegic athletes suffer from a neurogenic bladder and are regularly treated with 
intravesical oxybutynin instillations. As urine tampering including substitution and 
adulteration is prohibited in sports, such a medical intervention can potentially be considered 
as sample manipulation and a violation of anti-doping rules. Within this pilot study, it could be 
demonstrated that intravesical instillations with oxybutynin hydrochloride did not affect 
routine tests for a total of 25 model substances, and the method of bladder instillation as such 
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does not appear to require specific attention in the context of doping control procedures. 
However, future studies should clarify whether this also applies to bladder irrigation procedures 
with antiseptics such as chlorhexidine [14]. 
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Tables: 
Table 1: Information on the participants of the study and the collected samples 
(Sample NADA-XB-PO is missing) 
  
Sample # Sample code Gender pH
Specific 
gravity
Detection of 
Oxybutynin
Last bladder 
instillation before 
project start
Time between 
bladder 
instillation and 
sample collection
Oxybutynin: 
Volume 
Oxybutynin: 
Concentration
Oxybutynin: 
Amount
1 NADA-XA-P0 6.4 1.010 - 25 h 30 min - 20 mL 0.025% 5 mg
2 NADA-XA-P1 5.9 1.013 ++ 1 h 50 min
3 NADA-XB-P0 - - - 15 h 15 min - 12 mL 0.05% 6 mg
4 NADA-XB-P1 5.6 1.022 ++ 57 min
5 NADA-XB-P2 5.4 1.025 + 7 h 48 min
6 NADA-XB-P3 5.5 1.025 + 9 h 13 min
7 NADA-XC-P0 5.5 1.020 - 15 h 55 min - 10 mL 0.1% 10 mg
8 NADA-XC-P1 5.7 1.008 ++ 5 h 00 min
9 NADA-XC-P2 5.4 1.008 ++ 8 h 30 min
10 NADA-XD-P0 6.6 1.021 + 11 h 00 min - 7.5 mL 0.1% 7.5 mg
11 NADA-XD-P1 7.3 1.006 ++ 2 h 53 min
12 NADA-XD-P2 6.8 1.009 + 5 h 56 min
13 NADA-XD-P3 5.6 1.014 - 8 h 21 min
14 NADA-XE-P0 6.4 1.024 ++ 11 h 05 min - 7.5 mL 0.1% 7.5 mg
15 NADA-XE-P1 7.2 1.008 ++ 3 h 20 min
16 NADA-XE-P2 7.3 1.013 + 6 h 20 min
17 NADA-XF-P0 6.9 1.011 ++ 7 h 00 min - 15 mL 0.1% 15 mg
18 NADA-XF-P1 5.7 1.017 ++ 2 h 05 min
19 NADA-XF-P2 6.0 1.006 + 4 h 20 min
20 NADA-XF-P3 5.7 1.004 + 6 h 25 min
male
male
female
male
female
female
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Table 2: Results – Every urine sample (P0, P1, P2, and P3) was analyzed in triplicate: As 
provided by the respective participant (“Blank”), fortified with 25 different model compounds 
at a low concentration (“Low”), and fortified with 25 model concentrations at a medium 
concentration (“Medium”). The numbers indicate findings and total samples (first and second 
number, respectively) and results differing from full detection are highlighted in red. In the last 
table column, the number of adverse analytical findings reported in 2017 via ADAMS [13] is 
listed for each compound.  
 
 
 
  
P0 P1 P2 P3
Conc. 
[ng/mL] P0 P1 P2 P3
Conc. 
[ng/mL] P0 P1 P2 P3
Clenbuterol 0/5 0/6 0/5 0/3 2 5/5 6/6 5/5 3/3 10 5/5 6/6 5/5 3/3 294
NorOxandrolone 0/5 0/6 0/5 0/3 2 5/5 4/6 5/5 3/3 10 5/5 5/6 5/5 3/3 88
Boldenone-M 0/5 0/6 0/5 0/3 2 5/5 6/6 5/5 3/3 10 5/5 6/6 5/5 3/3 84
Drostanolone-M 0/5 0/6 0/5 0/3 2 5/5 6/6 5/5 3/3 10 5/5 6/6 5/5 3/3 119
Metenolone 0/5 0/6 0/5 0/3 2 5/5 6/6 5/5 3/3 10 5/5 6/6 5/5 3/3 64
S-22 (Ostarine) 0/5 0/6 0/5 0/3 20 5/5 6/6 5/5 3/3 100 5/5 6/6 5/5 3/3 47
Epi-/Trenbolone 0/5 0/6 0/5 0/3 1 2/5 2/6 3/5 1/3 5 5/5 6/6 5/5 3/3 65
Stanozolol 0/5 0/6 0/5 0/3 1 5/5 6/6 5/5 3/3 5 5/5 6/6 5/5 3/3 284
JWH018-carboxy 0/5 0/6 0/5 0/3 1 5/5 6/6 5/5 3/3 5 5/5 6/6 5/5 3/3 0
JWH018-hydroxy 0/5 0/6 0/5 0/3 1 5/5 6/6 5/5 3/3 5 5/5 6/6 5/5 3/3 0
Chlorothiazide 0/5 0/6 0/5 0/3 20 5/5 6/6 5/5 3/3 100 5/5 6/6 5/5 3/3 38
Furosemide 0/5 0/6 0/5 0/3 20 5/5 6/6 5/5 3/3 100 5/5 6/6 5/5 3/3 215
Hydrochlorothiazide 0/5 0/6 0/5 0/3 20 5/5 6/6 5/5 3/3 100 5/5 6/6 5/5 3/3 143
Canrenone 0/5 0/6 0/5 0/3 1 5/5 6/6 5/5 3/3 5 5/5 6/6 5/5 3/3 77
Dexamethasone 0/5 0/6 0/5 0/3 30 5/5 6/6 5/5 3/3 150 5/5 6/6 5/5 3/3 20
Triamcinolone acetonide 0/5 0/6 0/5 0/3 30 5/5 6/6 5/5 3/3 150 5/5 6/6 5/5 3/3 31
Prednisone 0/5 0/6 0/5 0/3 30 5/5 6/6 5/5 3/3 150 5/5 6/6 5/5 3/3 56
Fluticasone propionate 0/5 0/6 0/5 0/3 30 5/5 6/6 5/5 3/3 150 5/5 6/6 5/5 3/3 4
Methylprednisolone 0/5 0/6 0/5 0/3 30 5/5 6/6 5/5 3/3 150 5/5 6/6 5/5 3/3 13
Meldonium 0/5 0/6 0/5 0/3 20 5/5 6/6 5/5 3/3 100 5/5 6/6 5/5 3/3 79
Anastrozole 0/5 0/6 0/5 0/3 1 5/5 6/6 5/5 3/3 5 5/5 6/6 5/5 3/3 40
Amfetamine 0/5 0/6 0/5 0/3 100 5/5 6/6 5/5 3/3 1000 5/5 6/6 5/5 3/3 102
4-Methylhexan-2-amine 0/5 0/6 0/5 0/3 100 5/5 6/6 5/5 3/3 1000 5/5 6/6 5/5 3/3 50
Heptaminol 0/5 0/6 0/5 0/3 100 5/5 6/6 5/5 3/3 1000 5/5 6/6 5/5 3/3 16
rac-Methamfetamine 0/5 0/6 0/5 0/3 100 5/5 6/6 5/5 3/3 1000 5/5 6/6 5/5 3/3 6
Nikethamide 0/5 0/6 0/5 0/3 100 5/5 6/6 5/5 3/3 1000 5/5 6/6 5/5 3/3 1
Oxybutynin 3/5 6/6 5/5 2/3 3/5 6/6 5/5 2/3 3/5 6/6 5/5 2/3
Substance Group
AAFs in 
2017[13]
Model compound
Blank Low Medium
Stimulants (S6)
Anabolic Agents (S1)
Cannabinoids (S8)
Diuretics and Masking 
Agents (S5)
Glucocorticoids (S9)
Hormone and 
Metabolic Modulators 
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Figure 1
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Figure 1: Schematic overview of a bladder instillation with oxybutynin hydrochloride solution. 
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Figure 2
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Figure 2: Timeline of sample collection. 
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AA: 1.25E+07 AA: 1.49E+07 AA: 1.33E+07 AA: 1.35E+07
AA: 1.34E+06 AA: 2.21E+06 AA: 8.52E+05 AA: 1.37E+06
AA: 0.00E+00 AA: 0.00E+00 AA: 0.00E+00 AA: 0.00E+00
P0 P1 P2 P3
P0 P1 P2 P3
P0 P1 P2 P3
Low Low Low Low
Medium Medium Medium Medium
Hydrochlorothiazide (m/z = 295.9561; 10 ppm) 
RT: 5.06 RT: 5.06 RT: 5.06 RT: 5.06
RT: 5.07 RT: 5.07 RT: 5.09 RT: 5.08
Figure 3
 
 
Figure 3: Extracted ion chromatograms of the deprotonated molecule of the diuretic 
hydrochlorothiazide (m/z = 295.9561) for an exemplary sample set. All samples collected 
before (P0) and after intravesical instillation of oxybutynin hydrochloride (P1-P3) show no 
hydrochlorothiazide (top row). Hydrochlorothiazide could be detected unambiguously after 
addition in low (20 ng/mL, middle row) and medium concentration (100 ng/mL, bottom line) 
to the urine samples.  
 
 
 
 
